UK markets close in 4 hours 54 minutes

Kinarus Therapeutics Holding AG (0QNS.L)

LSE - LSE Delayed price. Currency in CHF
Add to watchlist
0.0154+0.0154 (+84.00%)
As of 04:07PM GMT. Market open.
Full screen
Previous close0.0000
Open0.0000
Bid0.0000 x N/A
Ask0.0000 x N/A
Day's range0.0000 - 0.0000
52-week range
Volume0
Avg. volumeN/A
Market cap32,522
Beta (5Y monthly)N/A
PE ratio (TTM)N/A
EPS (TTM)-0.0010
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • EQS Group

    Kinarus Therapeutics’ KIN001 Shows Strong Antiviral Activity Against SARS-CoV-2 Omicron Subvariants BA.2 and BA.5

    Kinarus Therapeutics Holding AG / Key word(s): Research UpdateKinarus Therapeutics’ KIN001 Shows Strong Antiviral Activity Against SARS-CoV-2 Omicron Subvariants BA.2 and BA.5 06.12.2022 / 07:00 CET/CESTMEDIA RELEASE Researchers at Friedrich-Alexander-Universität Erlangen-Nürnberg and Kinarus report new antiviral data of KIN001 against SARS-CoV-2 Omicron BA.2 and BA.5 subvariants KINFAST Phase 2 trial of KIN001 in ambulatory COVID-19 patients is actively recruiting Basel, Switzerland, 6 December

  • EQS Group

    Kinarus Receives USPTO Notice of Allowance for Lead Therapeutic Candidate KIN001

    Kinarus Therapeutics Holding AG / Key word(s): PatentKinarus Receives USPTO Notice of Allowance for Lead Therapeutic Candidate KIN001 22.11.2022 / 07:00 CET/CESTMEDIA RELEASE Method-of-use-patent covers KIN001 in ophthalmic diseases Further strengthens already granted KIN001 US composition of matter patent Basel, Switzerland, 22 November 2022. Kinarus Therapeutics Holding AG (SIX: KNRS) (“Kinarus”), a clinical-stage biopharmaceutical company developing novel therapeutics to treat viral, respirat

  • EQS Group

    Kinarus Therapeutics Engages Great Health Companion Group to Explore Partnerships in China

    Kinarus Therapeutics Holding AG / Key word(s): PartnershipKinarus Therapeutics Engages Great Health Companion Group to Explore Partnerships in China 16.11.2022 / 07:00 CET/CESTMEDIA RELEASE Kinarus to explore partnerships in China to fund Phase 2 clinical trials of KIN001 and explore further business opportunities Multiple opportunities for KIN001 in indications with high unmet need are well-matched to the Chinese marketBasel, Switzerland, 16 November 2022. Kinarus Therapeutics Holding AG (SIX: